This biotech developing a cholesterol drug has a chance to triple, RBC predicts

31,Oct,2023 | Investment | 0 comments

NewAmsterdam Pharma's "best-in-class" cholesterol treatment could lead to a more than $2 billion revenue opportunity, according to RBC. Originally published at CNBC

Submit a Comment

Your email address will not be published. Required fields are marked *

Small Business Minder
error: Content is protected !!